These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 35733032)

  • 1. A prospective cohort study of methotrexate plus idarubicin in newly diagnosed primary CNS lymphoma.
    Li Q; Ma Y; Lin Z; Ma J; Kang H; Zhang M; Xu H; Chen B
    J Neurooncol; 2023 May; 163(1):39-46. PubMed ID: 35733032
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Role of chemotherapy additional to high-dose methotrexate for primary central nervous system lymphoma (PCNSL).
    Bergner N; Monsef I; Illerhaus G; Engert A; Skoetz N
    Cochrane Database Syst Rev; 2012 Nov; 11():CD009355. PubMed ID: 23152274
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparing the Efficacy of DeVIC Therapy and High-dose Methotrexate Monotherapy with Whole-brain Radiation Therapy for Newly-diagnosed Primary Central Nervous System Lymphoma: A Single Institution Study.
    Chalise L; Motomura K; Ohka F; Hirano M; Hara M; Nishimura Y; Natsume A; Wakabayashi T
    Anticancer Res; 2017 Sep; 37(9):5215-5223. PubMed ID: 28870957
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High-dose methotrexate with or without rituximab in newly diagnosed primary CNS lymphoma.
    Holdhoff M; Ambady P; Abdelaziz A; Sarai G; Bonekamp D; Blakeley J; Grossman SA; Ye X
    Neurology; 2014 Jul; 83(3):235-9. PubMed ID: 24928128
    [TBL] [Abstract][Full Text] [Related]  

  • 5. First-line induction chemotherapy with high-dose methotrexate versus teniposide in patients with newly diagnosed primary central nervous system lymphoma: a retrospective, multicenter cohort study.
    Zhong K; Shi Y; Gao Y; Zhang H; Zhang M; Zhang Q; Cen X; Xue M; Qin Y; Zhao Y; Zhang L; Liang R; Wang N; Xie Y; Yang Y; Liu A; Bao H; Wang J; Cao B; Zhang W; Zhang W
    BMC Cancer; 2023 Aug; 23(1):746. PubMed ID: 37568079
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Outcome of patients with newly diagnosed primary CNS lymphoma after high-dose methotrexate followed by consolidation whole-brain radiotherapy and cytarabine: an 8-year cohort study.
    Piriyakhuntorn P; Rattanathammethee T; Hantrakool S; Chai-Adisaksopha C; Rattarittamrong E; Tantiworawit A; Norasetthada L
    Int J Clin Oncol; 2021 Oct; 26(10):1805-1811. PubMed ID: 34236556
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High-dose methotrexate monotherapy for newly diagnosed primary central nervous system lymphoma: 15-year multicenter experience.
    Yoon WS; Park JS; Kim YI; Chung DS; Jeun SS; Hong YK; Yang SH
    Asia Pac J Clin Oncol; 2021 Feb; 17(1):123-130. PubMed ID: 32978898
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High-dose methotrexate and rituximab induction regimen in immunocompetent patients with primary CNS lymphoma: a retrospective single-center study of survival predictors.
    DeAtkine AB; Abdelrashid M; Tucker Z; Mehta A; Markert JM; Kim J; Fiveash JB; Oster RA; Lobbous M; Nabors LB
    J Neurooncol; 2022 May; 158(1):33-40. PubMed ID: 35441948
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Methotrexate plus idarubicin improves outcome of patients with primary central nervous system lymphoma.
    Fan N; Zhang L; Xu X; Chen B; Zhu C; Li P; Chen Z; Ding T; Ma Y; Yuan Y; Lin Z
    Oncotarget; 2017 Aug; 8(32):53701-53713. PubMed ID: 28881844
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Improvement of outcomes of an escalated high-dose methotrexate-based regimen for patients with newly diagnosed primary central nervous system lymphoma: a real-world cohort study.
    Li Q; Ma J; Ma Y; Lin Z; Kang H; Chen B
    Cancer Manag Res; 2021; 13():6115-6122. PubMed ID: 34377030
    [TBL] [Abstract][Full Text] [Related]  

  • 11. White matter changes in primary central nervous system lymphoma patients treated with high-dose methotrexate with or without rituximab.
    Estephan F; Ye X; Dzaye O; Wagner-Johnston N; Swinnen L; Gladstone DE; Ambinder R; Kamson DO; Lambrecht S; Grossman SA; Lin DDM; Holdhoff M
    J Neurooncol; 2019 Dec; 145(3):461-466. PubMed ID: 31621040
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Evaluation of the Short-Term Efficacy and Safety of Orelabrutinib Combined with High-Dose Methotrexate in the First-line Treatment of Elderly Patients with High Risk Primary Central Nervous System Lymphoma].
    Xie Y; Qu S; Liao LS; Zheng ZH; Lin Y; Chen WM; Chen BY
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2023 Dec; 31(6):1714-1719. PubMed ID: 38071050
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High-dose methotrexate-based regimens and post-remission consolidation for treatment of newly diagnosed primary CNS lymphoma: meta-analysis of clinical trials.
    Yu J; Du H; Ye X; Zhang L; Xiao H
    Sci Rep; 2021 Jan; 11(1):2125. PubMed ID: 33483528
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A phase 1 dose escalation study of idarubicin combined with methotrexate, vindesine, and prednisolone for untreated elderly patients with primary central nervous system lymphoma. The GOELAMS LCP 99 trial.
    Olivier G; Clavert A; Lacotte-Thierry L; Gardembas M; Escoffre-Barbe M; Brion A; Cumin I; Legouffe E; Solal-Celigny P; Chabin M; Ingrand P; Colombat P; Delwail V
    Am J Hematol; 2014 Nov; 89(11):1024-9. PubMed ID: 25052698
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Analysis of Key Factors Associated with Response to Salvage High-Dose Methotrexate Rechallenge in Primary Central Nervous System Lymphoma with First Relapse.
    Du P; Chen H; Shen L; Liu X; Wu X; Chen L; Cao A; Geng D
    Curr Oncol; 2022 Sep; 29(9):6642-6656. PubMed ID: 36135091
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Continued-Maintenance Therapy with High-dose Methotrexate Improves Overall Survival of Patients with Primary Central Nervous System Lymphoma.
    Nakajima K; Mizobuchi Y; Fujihara T; Azumi M; Takagi Y
    J Med Invest; 2021; 68(3.4):286-291. PubMed ID: 34759146
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of contemporary regimens on the outcomes and toxicity of primary CNS lymphoma: a single-center retrospective analysis of 73 patients.
    Sarid N; Bokstein F; Blumenthal DT; Weiss-Meilik A; Gibstein L; Avivi I; Perry C; Ram R
    J Neurooncol; 2021 Jan; 151(2):211-220. PubMed ID: 33099747
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Therapeutic management of central nervous system lymphomas in a single hematological institute].
    Iványi JL; Marton E; Plander M; Gyánó G; Czumbil L; Tóth C
    Orv Hetil; 2009 Oct; 150(42):1937-44. PubMed ID: 19812012
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunochemotherapy using rituximab (RTX) and high-dose methotrexate (HD-MTX): an evaluation of the addition of RTX to HD-MTX in recurrent primary central nervous system lymphoma (PCNSL).
    Miyakita Y; Ohno M; Takahashi M; Muragaki Y; Katai H; Narita Y
    Jpn J Clin Oncol; 2017 Oct; 47(10):919-924. PubMed ID: 28981729
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical outcomes of newly diagnosed primary CNS lymphoma treated with ibrutinib-based combination therapy: A real-world experience of off-label ibrutinib use.
    Chen F; Pang D; Guo H; Ou Q; Wu X; Jiang X; Wei X; Liu S; Huang L; Liang Z; Zhou D; Li W
    Cancer Med; 2020 Nov; 9(22):8676-8684. PubMed ID: 33068336
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.